Ongoing clinical trials in ovarian cancer are evaluating inhibitors of multiple molecular pathways such as PI3K/AKT, the mTOR pathway, angiogenesis, the MAPK pathway, and the HER/EGFR pathway [27,28]. This evidence concerns the gene AKT1 and ovarian cancer.